[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568841":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":53,"collaborators":25,"id":55,"slug":25,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":25,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":25,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Telios Pharma, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TL-925 Arm","ACTIVE_COMPARATOR","Subjects will be dosed in clinic.",[13],"Drug: TL-925",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo Arm","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","TL-925","TL-925 is an eye drop.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"John Mei","CONTACT","(650) 542-0136","jmei@teliospharma.com",{"name":37,"role":33,"phone":25,"phoneExt":25,"email":38},"Yulia Khalina","ykhalina@teliospharma.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":25},"Telios Investigative Site","RECRUITING","Memphis","Tennessee","38119","United States",{"type":48,"coordinates":49},"Point",[50,51],-90.04898,35.14953,{"lat":51,"lon":50},{"type":54,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100568841",false,"NCT06686472","Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis","A Single-Center, Randomized, Double-masked, Vehicle-controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model","Inclusion Criteria:\n\n* Individuals aged 18 years or older\n* Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.\n* Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.\n* Calculated best-corrected visual activity of 0.7 LogMAR or better\n* Positive bilateral CAC reaction\n\nExclusion Criteria:\n\n* Any systemic or ocular disease currently producing ocular redness and\u002For ocular discomfort, or that may interfere with the conduct of the study.\n* Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months\n* Any ongoing ocular infection (bacterial, viral or fungal)","ALL","18 Years",{"count":64,"type":65},66,"ESTIMATED","INTERVENTIONAL",[68],"PHASE2","In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.\n\nThe study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.",[71],"Allergic Conjunctivitis","2024-11-11",{"date":74,"type":75},"2024-11-13","ACTUAL",{"date":77,"type":75},"2024-10-03",{"date":79,"type":65},"2024-12-10",{"name":5,"class":6},1]